pubmed-article:3818496 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:3818496 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:3818496 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
pubmed-article:3818496 | lifeskim:mentions | umls-concept:C0025893 | lld:lifeskim |
pubmed-article:3818496 | lifeskim:mentions | umls-concept:C0277785 | lld:lifeskim |
pubmed-article:3818496 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:3818496 | pubmed:dateCreated | 1987-4-1 | lld:pubmed |
pubmed-article:3818496 | pubmed:abstractText | The pharmacokinetics of mezlocillin were investigated in 26 patients with alcoholic liver disease. Serum concentrations of mezlocillin were measured following intravenous administration of 3 g doses over 30 min. The mean peak serum concentration (+/- standard deviation) of mezlocillin at the end of infusion was 138.8 +/- 55.7 mg/l and the mean terminal half-life (T 1/2 beta) was 2.10 +/- 0.9 h. The 24 h urinary recovery of mezlocillin was 35.4 +/- 12.4% of the administered dose. Serum clearance was found to be inversely correlated with alkaline phosphatase and with total bilirubin. The T 1/2 beta was related to the following clinical measurements: age, SGOT and prothrombin time. This relationship suggests it may be prudent to adjust the dosage and the dosage interval of mezlocillin in patients with hepatobiliary dysfunction. | lld:pubmed |
pubmed-article:3818496 | pubmed:language | eng | lld:pubmed |
pubmed-article:3818496 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3818496 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:3818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:3818496 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:3818496 | pubmed:month | Dec | lld:pubmed |
pubmed-article:3818496 | pubmed:issn | 0305-7453 | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:WornerT MTM | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:HirschmanS... | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:JacobsonJJ | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:SacksH SHS | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:MeyersB RBR | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:WormserG PGP | lld:pubmed |
pubmed-article:3818496 | pubmed:author | pubmed-author:SrulevitchE... | lld:pubmed |
pubmed-article:3818496 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:3818496 | pubmed:volume | 18 | lld:pubmed |
pubmed-article:3818496 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:3818496 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:3818496 | pubmed:pagination | 709-13 | lld:pubmed |
pubmed-article:3818496 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:meshHeading | pubmed-meshheading:3818496-... | lld:pubmed |
pubmed-article:3818496 | pubmed:year | 1986 | lld:pubmed |
pubmed-article:3818496 | pubmed:articleTitle | Pharmacokinetics of mezlocillin in patients with hepatobiliary dysfunction. | lld:pubmed |
pubmed-article:3818496 | pubmed:publicationType | Journal Article | lld:pubmed |